212 related articles for article (PubMed ID: 23370169)
21. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
[TBL] [Abstract][Full Text] [Related]
22. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
[TBL] [Abstract][Full Text] [Related]
23. Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.
Kaur I; Kosak KM; Terrazas M; Herron JN; Kern SE; Boucher KM; Shami PJ
Pharm Res; 2015 Apr; 32(4):1395-406. PubMed ID: 25330743
[TBL] [Abstract][Full Text] [Related]
24. Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.
Folaron M; Seshadri M
Mol Imaging Biol; 2016 Dec; 18(6):860-869. PubMed ID: 27160251
[TBL] [Abstract][Full Text] [Related]
25. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
26. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
[TBL] [Abstract][Full Text] [Related]
27. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
28. Protein phosphatase 2A activation mechanism contributes to JS-K induced caspase-dependent apoptosis in human hepatocellular carcinoma cells.
Liu L; Huang Z; Chen J; Wang J; Wang S
J Exp Clin Cancer Res; 2018 Jul; 37(1):142. PubMed ID: 29986744
[TBL] [Abstract][Full Text] [Related]
29. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
Sjödin B; Mannervik B
Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
[TBL] [Abstract][Full Text] [Related]
30. JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer.
Zhao X; Cai A; Peng Z; Liang W; Xi H; Li P; Chen G; Yu J; Chen L
J Cell Mol Med; 2019 Apr; 23(4):2489-2504. PubMed ID: 30672108
[TBL] [Abstract][Full Text] [Related]
31. JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.
Qiu M; Ke L; Zhang S; Zeng X; Fang Z; Liu J
Cancer Chemother Pharmacol; 2017 Aug; 80(2):275-286. PubMed ID: 28608259
[TBL] [Abstract][Full Text] [Related]
32. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Luo Y; Jiang F; Cole TB; Hradil VP; Reuter D; Chakravartty A; Albert DH; Davidsen SK; Cox BF; McKeegan EM; Fox GB
Cancer Chemother Pharmacol; 2012 Apr; 69(4):911-21. PubMed ID: 22080168
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
Nandurdikar RS; Maciag AE; Citro ML; Shami PJ; Keefer LK; Saavedra JE; Chakrapani H
Bioorg Med Chem Lett; 2009 May; 19(10):2760-2. PubMed ID: 19364650
[TBL] [Abstract][Full Text] [Related]
34. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas.
Weyerbrock A; Walbridge S; Pluta RM; Saavedra JE; Keefer LK; Oldfield EH
J Neurosurg; 2003 Oct; 99(4):728-37. PubMed ID: 14567609
[TBL] [Abstract][Full Text] [Related]
35. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
36. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
[TBL] [Abstract][Full Text] [Related]
37. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
Kumar V; Hong SY; Maciag AE; Saavedra JE; Adamson DH; Prud'homme RK; Keefer LK; Chakrapani H
Mol Pharm; 2010 Feb; 7(1):291-8. PubMed ID: 20000791
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro.
Weyerbrock A; Baumer B; Papazoglou A
J Neurosurg; 2009 Jan; 110(1):128-36. PubMed ID: 18991497
[TBL] [Abstract][Full Text] [Related]
39. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study.
Côté J; Savard M; Bovenzi V; Dubuc C; Tremblay L; Tsanaclis AM; Fortin D; Lepage M; Gobeil F
Neuropeptides; 2010 Apr; 44(2):177-85. PubMed ID: 20080302
[TBL] [Abstract][Full Text] [Related]
40. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]